Cannabis Science, Inc. (OTC Bulletin Board: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce the partnership with The Unconventional Foundation for Autism (UF4A) to build on the Foundation's success with its proprietary cannabinoid formulations for Autism treatment. The partnership will focus on advancing the medical cannabis treatments for Autism in conjunction with the successful cannabis treatments of Joey and 10 other families that are now being documented by The University of California Irvine Medical Center (UCI) for the Foundation.

These successful Autism treatments and pioneering efforts of Joey's Mom, Mieko Hester Perez, can be fully reviewed at

Mieko and the successful treatment of her son has garnered wide-spread media interest including television appearances and interviews with KABC 7 - Los Angeles & San Francisco, 20/20 ABC, Good Morning America, Fox Morning News, Fox News Rhode Island, CBS Early Show, KCAL 9 & CBS 2 Los Angeles, The Doctor's TV Show, KABC 790 w/ Peter Tilden, Montel Williams, The Tom Joyner Show, The Kim Frasier Show w/ Dr. Lester Grinspoon, The Bill Press Show, NORML's Podcast w/ Russ Belville, Thomasina Tafur radio show. Featured interviews: Autism Spectrum Magazine, Treating yourself Magazine, Huffington Post, Autism Spot, Celebstoner, disability scoop, Autism Support Network, Kush Magazine August 2010 Issue Cover, High Times Medical Marijuana Magazine Winter 2011 Issue, Treating yourself Magazine (Joey's sibling interviewed Issue #23, Weed World UK Issue #89, Now Magazine UK Publications, Medical Cannabis Journal Issue, LA JEMM - Ethical Use of Medical Marijuana in the Treatment of Children with Autism, Orange County Register, California, The Revolution - Argentina publication. 2010 Recognized by the National Organization to Reform Marijauna Laws Woman's Alliance as one of the woman making history in the medical marijuana movement.

Mieko Hester Perez, Founder and Executive Director of The Unconventional Foundation for Autism (UF4A) stated, ?We believe that this new partnership with Cannabis Science will give us additional push and resources required to advance our Autism research. To date, we have already partnered with the University of California Irvine Medical Center to oversee our cannabis-based Autism research. Included in this group of advisors is the Dean of Medicine at UCI, and child psychiatrist Dr. Rebecca Hedrick M.D. Dr. Melamede of Cannabis Science will be an outstanding addition to the Board of the Foundation. His extensive knowledge of cannabinoid science should prove invaluable in our mission.?

As part of the new partnership, Dr. Robert Melamede, CEO of Cannabis Science, will be joining the board of UF4A as a scientific advisor. Dr. Melamede will work with UF4A to further assist in documenting the case studies and oversee the deployment of the Company's proprietary cannabinoid treatments on Autism patients alongside UF4A and medical professionals. He will also work with UF4A's legal advisors to progress the legalization of medical marijuana initiatives.

Dr. Robert Melamede Ph.D., Cannabis Science Inc., President & CEO, stated, ?Cannabis Science's partnership with UF4A is another instrumental step in reaching our long-term goal of FDA approval of the Company's products. The successful results from the Autism patients treated as documented by UF4A are very encouraging and we're excited to tap into UF4A's proven track record; providing our scientific expertise to help develop more refined treatment plans with Cannabis Science's formulations and extracts to achieve scientifically accepted patient outcomes. I'm also extremely excited to be working with the medical professionals at the University of California Irvine. This is a win-win for both our organizations in breaking new ground for medical cannabis treatments. Our partnership will enable both our Company and UF4A to expound upon studies and anecdotal evidence obtained by UF4A in order to catalogue verified case studies and solid science behind the treatment plans. This evidentiary step will help the UF4A and Cannabis Science partnership to move towards formal FDA testing to officially approve UF4A's successful treatments of Autism using medical cannabinoid extracts and formulations under the direction of physicians. ?

UF4A Case Studies

Mieko Hester-Perez and her son ?Joey? have inspired many additional parents with autistic children to step forward. Studies are underway with these children with oversight from Child & Adolescent Psychiatrist Dr. Rebecca M. Hedrick, M.D.

Dr. Hedrick is a child and adolescent emergency attending physician and covers the consult liaison service at UCI Medical. She runs a child and adolescent outpatient psychotherapy and medication management program. She also works with the Regional Center of Orange County in the treatment of individuals with developmental disabilities.

Associate Training Director, Psychiatry & Human Behavior School of Medicine M.D., Phone: (714) 456-8775 Fax: (714) 456-7605 Email:

About UF4A

The Unconventional Foundation for Autism, UF4A for short, is a non-profit organization. The mission of UF4A is three fold: (1) to raise awareness and support for families afflicted with this mysterious and misunderstood condition known as Autism; (2) to raise funds for cannabis-based medical research and clinical trials; and (3) to campaign for a rescheduling of cannabis from Schedule 1 narcotic (no accepted medical benefits) to a lower schedule so that the appropriate research may be conducted, and so that all patients have access to medication. A listing on Schedule 1 is tantamount to a research blockade and, frankly, is unacceptable where millions continue to needlessly suffer and subject to criminal punishment should they choose to use cannabis under the direction of their physician. The Schedule 1 listing fails to reflect the prevailing medical view that cannabis has accepted medical benefits. UF4A is quickly becoming a leading advocate in the fight for nationwide investigation, research and analysis of the legalization of Medical Marijuana.

The partnership promises to advance the innovative medical autism research headed by Executive Director Mieko Hester- Perez. The Unconventional Foundation Autism's partnership focus is to bridge the gap between parents, scientists, and medical professionals to provide a better quality of life for our children diagnosed with the misunderstood condition known as Autism.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
Mark J. Friedman
Investor Relations
1-877-431-CBIS (2247)